Ardigen

Executive Summary

Ardigen is a Poland-based AI-powered Contract Research Organization (CRO) founded in 2015. The company leverages artificial intelligence and bioinformatics to transform complex biomedical data into actionable insights for drug discovery and precision medicine. With over 100 clients, including major pharmaceutical companies, and more than 520 completed projects, Ardigen has established itself as a reliable partner in the AI-driven drug development space. The company's platform integrates machine learning algorithms with proprietary datasets to accelerate target identification, biomarker discovery, and patient stratification. By combining computational expertise with deep biological knowledge, Ardigen enables its clients to reduce R&D costs and shorten development timelines. The company is privately held and has not disclosed funding or valuation, but its strong client base and project pipeline suggest steady growth. As the adoption of AI in pharma continues to expand, Ardigen is well-positioned to capture a larger share of the CRO market, particularly in immuno-oncology and rare diseases. However, competition from other AI-native CROs and big pharma's internal AI capabilities may limit its upside. Overall, Ardigen represents a compelling opportunity in the AI for drug discovery space, with a proven business model and a growing reputation for delivering value.

Upcoming Catalysts (preview)

• Q3 2026Launch of advanced AI platform for immuno-oncology biomarker discovery80% success
• Q4 2026Strategic partnership with a top-10 pharmaceutical company for multi-year AI collaboration60% success
• Q1 2027Completion of Series B funding round to accelerate global expansion70% success